Treatments used in the control groups included placebo, usual care, and non-TZD antidiabetic therapies.
控制组的治疗方案包括安慰剂,常规护理和非噻唑啉二酮类药物抗糖尿病治疗。
The adjusted hazard ratios associated with TZD use were 1.0 for HF hospitalization and 0.98 for mortality.
应用TZDs的患者,心衰住院的调整危险比为1.0,心衰死亡率的调整危险比为0.98。
Those who initiated TZD therapy more than 5 years previously were more than twice as likely to develop bladder cancer than those who initiated SU therapy at the same time point.
之前起始TZD治疗超过5年的患者,与同样时间点起始SU治疗的患者相比,发生膀胱癌的风险增加超过2倍。
应用推荐